Phase 4: Therapeutic dose (Weeks 13-16) Dose: 8 mg or 9 mg once weekly What to expect: Strong appetite suppression Significant ongoing weight loss Possible temporary GI flare during escalation Many reach 10-15% weight loss by this phase Tips: This is where most people stabilize 8 mg may be sufficient for manyhigher isn't always better Continue lifestyle optimization Regular check-ins with healthcare provider Phase 5: Maximum dose (Week 17+) Dose: 12 mg once weekly (if tolerated and needed) What to expect: Maximum therapeutic effect Continued weight loss (averaging 20%+ by 48 weeks in trials) GI side effects may be manageable or may persist Some achieve 25-30%+ weight loss Tips: Not everyone needs to reach 12 mg Lower doses may provide sufficient results Balance efficacy with tolerability Maintenance may involve dose reduction For general peptide dosing principles, see our peptide dosage calculator guide

For patients with liver disease or sleep apnea, these exceptions may intersect with care delivered in our MASLD (fatty liver) clinic in Chula Vista and Sleep Apnea & Weight clinic
There is no published guidance on monitoring, no validated stopping rule, and no human safety threshold to reference
The PARP 1-17 family of poly-ADP ribose polymerases regulate DNA repair and nuclear stability
If a doctor determines that Rybelsus is essential for your type 2 diabetes management, your insurance plan may be more likely to cover it
"Obesity care is specialty care and deserves dedicated infrastructure," said Dr